Abstract
Head and neck dermatitis (HND) is a form of atopic dermatitis (AD) that affects the seborrheic areas of the body and causes greater quality of life detriments than other types of AD. HND can be challenging to treat since first-line topical therapies may be ineffective or intolerable for long-term use on areas affected by HND while dupilumab may cause dupilumab-associated HND (DAHND). Current evidence implicates fungi, particularly Malassezia spp., in the pathogenesis of HND. Penetration of fungal antigens through the defective AD skin barrier activates the innate and adaptive immune systems to cause cutaneous inflammation via the T helper (Th)17 and/or Th2 axes. Malassezia sensitization may distinguish HND from other forms of AD. Multiple double-blind, placebo-controlled trials have shown antifungals to benefit HND, yet the persistence of symptom relief with sustained use remains unclear. Oral antifungals appear more effective than topical antifungals but may be harmful with long-term use. DAHND may also be fungal-mediated given improvement with antifungals and evidence of an overactive immune response against Malassezia in these patients. Janus kinase inhibitors are effective for HND, including DAHND, but may cause significant side effects when administered systemically. OX40/OX40L inhibitors and tralokinumab may be promising options for HND on the horizon. Demographic and environmental factors influence the host mycobiome and should be considered in future precision-medicine approaches as microbiome composition and diversity are linked to severity of HND.
Keywords: Atopic dermatitis, Head and neck dermatitis, Fungi, Malassezia, Dupilumab-associated head and neck dermatitis, Th17
Introduction
AD is a chronic inflammatory and pruritic skin condition with substantial physical, psychosocial, and financial burden for patients and their caregivers [1–6]. HND is a subtype of AD that primarily affects the seborrheic areas of the body including the head, face, neck, and upper trunk [7–9]. Among AD patients, up to 36% of adults and 79% of children may be affected [7, 10, 11]. HND is associated with greater health-related quality of life burden in both adults and children compared to AD of other distributions [12]. Importantly, involvement of the head, neck, and facial regions has a greater impact on quality of life than objective severity score and total body surface area affected [12]. In the context of AD patient input that wearing occlusive clothing benefits their mental health, cosmetic appearance is likely a major contributor to low quality of life in HND given the highly visible distribution of lesions [2, 12, 13]. Two phenotypes may exist including adolescent-onset HND with exclusive head and neck involvement and adult-onset HND, which may accompany diffuse dermatitis [14].
Conventional AD treatments may be suboptimal for HND. Topical corticosteroids are the mainstay of AD management [15] but may cause facial skin atrophy, perioral dermatitis, or topical corticosteroid withdrawal [16–18]. Meanwhile, topical calcineurin and phosphodiesterase-4 inhibitors may improve some HND, but their use is limited by burning and stinging at the application site, which may be particularly bothersome on the face and neck [19, 20]. Since its introduction in 2017, the biologic dupilumab has been life-changing for many AD patients with moderate-to-severe AD refractory to topical medications. However, dupilumab is increasingly documented to exacerbate or even cause HND in a subset of patients, resulting in treatment discontinuation in around 11% of cases [21–25]. Dupilumab-associated HND (DAHND) may affect 29% of children and 6% of adults [26, 27], and no standard treatment for this complication exists [24]. Interestingly, HND is common among AD patients with exacerbations despite biological therapy [28], suggesting that HND represents a refractory and perhaps mechanistically distinct subset of AD.
The microbiome is increasingly accepted as a key factor in AD, and microbiome profiles cluster differently by disease presence and severity [29, 30]. Currently, bacterial contributions (i.e., Staphylococcus aureus) are the most explored and recognized [31, 32]. However, growing evidence implicates fungi, especially Malassezia spp., in HND [33], and both Th2 and Th17 axis mechanisms have been proposed [34, 35]. Understanding how fungi cause or exacerbate HND may enable more effective and upstream therapies for this disease and guide the development of AD therapeutics without DAHND-type reactions. Our review summarizes the current understanding of fungal contributions to HND and discusses rational medical management of this condition.
Malassezia
Malassezia Colonization Patterns
Genetic sequencing has revealed at least 11 fungal genera on human skin including commensals Malassezia, Rhodotorula, Debaryomyces, Cryptococcus, and Candida [36]. Among cutaneous fungi, Malassezia is predominant at 11 core-body and arm sites including the retroauricular crease, nares, and occiput despite differences in species representation between sites [36]. Malassezia spp. are lipophilic yeasts dependent on exogenous lipids given their lack of fatty acid synthase [34, 37]. Thus, sebaceous areas of the skin are more favorable for their growth [38–40]. Malassezia colonization increases over the first year of life before remaining static [41, 42] until puberty, when progression occurs rapidly due to the increase in androgens and accompanying elevation of sebum production [43]. By adulthood, Malassezia spp. represent between 53 and 80% of all fungi depending on the body area and may be found in the highest numbers behind the ear [44]. Malassezia colonization increases with age [45], and males show higher cutaneous Malassezia abundance [42, 46], likely due to greater sebum production versus females [47, 48].
The environment (i.e., temperature, humidity, air pollution) has an established role in modulating AD, which may include affecting mycobiome composition [31, 33]. Both low and very high temperatures and humidity are known to trigger AD in addition to exposure to indoor heating [31]. In a cohort of Japanese scientists journeying to Antarctica, Sugita et al. found increases in Malassezia colonization across body sites and most dramatically on the scalp with predominance of M. restricta [49]. Similarly, astronauts traveling to space show an increased ratio of Malassezia to all fungi on the skin [50]. Meanwhile, a study comparing Singaporean and Swiss mycobiomes observed that tropical (humid) climates promote Malassezia colonization and fungal species diversity [51]. Air pollution including particulate matter and gaseous pollutants is also now a recognized contributor to AD [52–55], and fungal dysbiosis due to these pollutants may represent a possible mechanism for AD worsening with air pollution [56, 57].
Representation of specific Malassezia spp. varies with demographic, micro-environmental (i.e., location on body), and macro-environmental (i.e., location on planet) factors. Regarding age and body part, M. globosa is more frequently cultured from younger patients and along the scalp and forehead, while M. sympodialis is more commonly found in adult patients and along the skin of the back [45]. This may be related to changes in skin lipid and pH profiles with age [48, 58]. Further, the diversity of Malassezia may vary across patients of different geographic locations and ethnicities. For instance, Singaporean subjects carry more species of Malassezia on average than those living in Switzerland [59, 60]. M. sympodialis is commonly isolated from the chest, back, face, and scalp of subjects living in Poland, Sweden, and other temperate climates while M. globosa is more encountered in warmer climates [45, 61, 62]. These findings illustrate the variability of Malassezia spp. representation among patients, supporting the existence of species-specific niches that may depend on myriad factors including temperature, humidity, ultraviolet exposure, presence of other microorganisms, availability of specific metabolites, and beyond.
Malassezia spp. diversity and relative abundance may be relevant to AD. AD lesions show greater diversity of Malassezia spp. compared to the skin of healthy individuals [63, 64]. Among AD patients, M. globosa and M. restricta may be more abundant than M. sympodialis [33]. Further, changes in the mycobiome composition may correspond with disease severity [29]. In adult HND patients living within the same geographic region (Japan), the number of Malassezia spp. observed is similar across disease severities but the relative abundance of each species varies [58]. HND patients with mild-to-moderate disease show a greater abundance of M. restricta versus M. globosa colonization in skin lesions [58] similar to between-flare AD skin [65]. In contrast, severe HND lesional skin features equal proportions of the two species [58]. Thus, a rising proportion of M. globosa to M. restricta could signal a shift towards severe disease in HND.
AD Predisposes to Cutaneous Malassezia Allergenicity
AD patients exhibit a skin surface pH that is up to 0.9 pH units higher than the mean healthy control skin pH of 5.24 [66, 67]. Alkaline pH not only fosters Malassezia growth [18] but also increases Malassezia antigen production, for example of the major allergen Mala s 12 by M. sympodialis [68]. Meanwhile, AD skin features decreased levels of antimicrobial/antifungal peptides including cathelicidins (i.e., LL37) and β-defensins [69–71], which may bias towards overactivation of Th17 and/or Th2 axis immunity [18]. However, further clarification may be needed since dendritic cells in severe AD have been observed to exhibit enhanced LL37 secretion in response to M. sympodialis exposure versus milder AD and healthy controls [72]. Cytokine gene variants (i.e., interleukin(IL)-10 and interferon(IFN)γ) may also increase susceptibility to Malassezia infection [73], and these have been associated with AD [31, 74, 75].
According to skin prick tests (SPTs), specific immunoglobulin E (sIgE) tests, or atopy patch tests (APTs), 67% of AD patients may be sensitized to Malassezia versus 0% of healthy controls [76]. This is consistent with the increased sensitization to many inhalant, food, and microbial allergens in AD due to the inherent skin barrier defects and increased propensity of atopic patients to mount immune responses to allergens [77, 78]. Among AD patients, Malassezia spp. sIgE is found more frequently in males and adults [34, 79], consistent with aforementioned trends of increased Malassezia colonization in males and with increased age. Sensitization to Malassezia is more common in HND versus other types of AD or healthy controls [80, 81]. In fact, sIgE to M. furfur has been reported in up to 100% of HND patients versus 13.6% of AD patients with other lesional distributions [80]. Thus, immunogenicity against Malassezia spp. is a typical feature in HND, and HND may be mechanistically distinct from other forms of AD.
Paradoxically, multiple studies have found that cutaneous Malassezia is diminished in AD patients versus healthy controls [33, 62, 82]. Moreover, among AD patients, fewer positive Malassezia cultures and lower colony-forming unit counts are obtained in lesional versus non-lesional skin [62, 82]. These observations may be explained by the dysregulated immune state of AD that is still microbicidal by nature and may actively suppress Malassezia expansion [35, 83]. Indeed, AD patients with positive SPTs or sIgE against M. sympodialis are less often positive in Malassezia cultures [62], supporting the theory that immune activation against Malassezia in AD may explain diminished Malassezia numbers in an otherwise favorable environment. Notably, Malassezia colonization is two-to-fivefold higher in severe HND skin versus mild-to-moderate HND and healthy skin [58]. We theorize that severe HND may be triggered by periods of Malassezia proliferation that potentiate the immune response [35, 72]. As control over Malassezia is obtained, the disease may return to a milder severity characterized by smoldering inflammation and lowered Malassezia presence.
Malassezia Pathophysiology
Malassezia spp. are skin commensals that are normally tolerated by the human immune system [84]. In AD however, the defective skin barrier and hyperactive immune system result in immune activation against the yeast. AD is characterized by a compromised skin barrier due to deficient stratum corneum components and decreased keratinocyte differentiation [31]. Compared to non-HND AD and control patients, HND skin is further deficient in ceramides such as esterified omega-hydroxyacyl-sphingosine, which typically maintain skin barrier integrity and have antifungal properties against Malassezia [81, 85]. Upon entering the skin, Malassezia antigens may trigger cutaneous inflammation through the Th17 and/or Th2 axis (Fig. 1). From a Th17 perspective, Malassezia antigen may trigger neutrophil or monocyte release of IL-23, resulting in Th17 or innate lymphoid cell release of IL-17 and a dysregulated inflammatory antifungal response [35]. In support, Malassezia-specific Th17 memory T cells are more abundant and reactive in AD patients versus healthy individuals [35]. From a Th2 perspective, dendritic cells may present fungal antigen to Th2 cells, triggering the release of IL4 and IL13, B-cell class switching, maturation to IgE-producing plasma cells, and ultimately an allergic IgE-mediated response [34]. In support, Malassezia sIgE levels have been shown to be positively associated with clinical severity of HND [86]. Further, a genotyping study identified four HLA risk alleles and two protective alleles for Malassezia-related skin diseases including HND, suggesting that abnormal antigen presentation may have a role [87]. However, Sparber et al. observed that Th2 cytokines including IL-5, IL-13, and TSLP were unchanged or decreased with cutaneous M. pachydermatis exposure in mice, which may favor Th17 over Th2 activation as the mechanism of fungal-driven AD.
Fig. 1.
Current mechanistic theories for fungal-driven head and neck dermatitis
Various antigens and antigen-specific mechanisms have been proposed for fungal AD. Mala s 11, Mala s 12, and Mala s 13 are potential major allergens for AD patients sensitized to M. sympodialis and may result in cross-reactivity with human manganese superoxide dismutase, the glucose-methanol-choline oxidoreductase enzyme superfamily, and human thioredoxin, respectively [34, 88–90]. M. sympodialis antigens may also augment AD mast cell release of IL-6 [91], a cytokine known to increase numbers and reactivity of mast cells [92], thus potentiating an allergic response. M. globosa MGL_1304 has been identified as a major histamine-releasing antigen in human sweat and may explain why sweating triggers cutaneous symptoms in some AD patients [93]. M. sympodialis Mala s 8 and M. restricta Mala r 8 are homologous to MGL_1304 and have also been implicated in HND [94]. M. globosa glycoprotein Mal g 46b is another potential major antigen in AD patients [95]. Finally, M. furfur secretes proteases (i.e., human secretory aspartyl protease MGSAP1) that may contribute to inflammation, increase virulence, and facilitate colonization [96].
Non-Malassezia Fungi
Non-Malassezia Diversity
Many non-Malassezia fungi have been recovered from AD skin, including Candida, Cryptococcus, Trichosporon, Saccharomyces, Meyerozyma, Rhodotorula, Debaryomyces, Aureobasidium, Penicillium, and Geotrichum [29, 97]. In fact, non-Malassezia fungi are more diverse in AD skin as compared to the skin of healthy individuals [29, 98]. AD patients have higher rates of Candida, Cryptococcus, and Geotrichum candidum colonization when compared to healthy individuals [29, 97, 99–101]. The proportion of C. diffluens and C. liquefaciens isolated from AD patients is almost twice that of healthy subjects [102]. Interestingly, severe AD skin is more often colonized with non-Malassezia fungi than mild-to-moderate AD skin [30]. In severe disease, the relative abundance of Malassezia may be decreased in favor of Candida, Debaryomyces, Aureobasidium, and Penicillium when compared against mild-to-moderate AD or healthy controls [30]. Some organisms including C. albicans, C. diffluens, and C. liquefaciens may be unique to AD patients and not present on healthy skin [29].
Non-Malassezia Pathophysiology
Several non-Malassezia species associated with AD have received limited attention for potential roles in disease pathogenesis. One study showed that 35% and 40% of AD patients have sIgE against Cryptococcus diffluens and Cryptococcus liquefaciens, respectively, suggesting that components of these organisms could play a role in AD or provoke hypersensitivity responses [103]. In patients with AD, the mannan of C. albicans may induce elevated IL-2 and IFNγ responses that may contribute to the pathogenesis of the disease [104]. Lastly, though the role of Trichophyton in the pathophysiology of AD is not well understood, 79% of AD patients with dermatophyte infections experience an immediate hypersensitivity reaction against Trichophyton antigen [105].
Dupilumab-Associated HND
Dupilumab is an IgG monoclonal antibody that targets the α subunit of IL-4 and IL-13 receptors, blocking the Th2 axis that is central to AD pathogenesis [106]. DAHND is most often reported as new onset or acute worsening of head and facial erythema and pruritus after dupilumab therapy [107] and may occur 10–39 weeks after initiation of dupilumab treatment [108] (Fig. 2). DAHND has also been called new regional dermatoses, dupilumab facial redness, paradoxical head and neck erythema, and persistent facial dermatitis [25]. Biopsy shows ectatic capillaries and perivascular lymphocytic exocytosis without spongiosis [108]. Mast cells, T cells, and histiocytes occur in normal numbers, and plasma cell counts are variable [108]. Meanwhile, only small numbers of eosinophils are present, and B cells, neutrophils, and macrophages are largely absent [108].
Fig. 2.
A DAHND 3 months after starting dupilumab 300 mg every 2 weeks. B Almost complete resolution after treatment with itraconazole 100 mg daily for 21 days. Dupilumab was not discontinued
A potential explanation for DAHND may be the shift towards Th17/Th22 antifungal immunity in AD patients treated with dupilumab [18, 109–111]. The Th2 cytokine IL-13 is thought to maintain homeostasis between the host and Malassezia colonization [18]. Blocking the Th2 pathway with dupilumab may skew immunity towards the highly antifungal Th17/Th22-mediated pathway, generating an immune response against commensal Malassezia [18, 110]. In support, a recent cohort study found that Malassezia colonization on the forehead decreased following dupilumab administration despite continued predominance of M. restricta and M. globosa over the cutaneous mycobiome [112]. Meanwhile, in a punch biopsy study of human DAHND skin where DAHND was defined as de novo HND following dupilumab commencement, CCR7 ligand CCL21 was upregulated in DAHND smooth muscle cells and contributed to Th17 chemotaxis [109, 113]. Th17 overactivation against Malassezia is further supported by increased Malassezia-specific Th17 memory T cells in the blood of AD patients [35]. Meanwhile, DAHND skin biopsy also revealed increased Th22 markers in oligoclonal expanded T cells and enhanced keratinocyte activation with IL-22 receptor upregulation [109]. Notably, a prospective study by Kozera et al. showed that patients who develop DAHND have significantly greater levels of serum Malassezia sIgE compared to those who do not (median 31.95 kU/Lversus 2.27 kU/L; P = 0.005) despite no differences in serum total IgE between groups at baseline (4570 kU/L versus 4478 kU/L; P = 0.95) [24]. This study defined DAHND as de novo or worsening HND after starting dupilumab (worsening was defined as 50% worsening in head and neck Eczema Area and Severity Index (EASI) score). Further research is necessary to confirm if Malassezia sIgE plays a direct role in DAHND or if it may function as a biomarker of disease severity.
From a treatment perspective, Kozera et. al showed that DAHND may temporarily improve with oral itraconazole therapy and that Malassezia sIgE levels mirror clinical improvement, supporting hyperactive immunity against Malassezia spp. as a feature of DAHND (Fig. 2). Interestingly, the anti-IL13 antibody tralokinumab improves AD in some patients who developed HND with dupilumab [114] and may be safe and effective for short-term use in HND [115]. Thus, IL-13 blockade alone may not be sufficient to trigger Th17/Th22 overactivation, and IL-4 or IL-4 receptor α blockade may be required as with dupilumab. Other proposed mechanisms for DAHND include underlying contact dermatitis, rosacea via Dermodex proliferation, and psoriasiform dermatitis, although these have not been well-studied [116].
Diagnosis
Clinically, Malassezia hypersensitivity may be suspected in patients with AD and head and neck lesions [117]. AD exacerbations during adolescence or young adulthood, severe lesions recalcitrant to conventional therapy, and comorbid atopic disease may be supportive features [117]. Dupilumab initiation up to 9 months prior to symptom onset may be considered suggestive of DAHND [108]. Sensitization tests may be useful to determine the etiology of HND, although Malassezia sensitization accompanies most HND [18, 86]. Currently, SPT, sIgE testing, and APT for Malassezia spp. [76] are not established components of the AD workup, but positivity may lend support to a diagnosis of fungal HND. Polymerase chain reaction (PCR) is another promising tool for diagnosis of fungal HND and offers rapid (around 72–96 h if sequencing is performed for species identification) and specific results. In relation to Malassezia spp., the main molecular target for PCR is internal transcribed spacer 1 (ITS1), which allows for sequencing to identify specific species. Skin scales obtained through scraping or tape-stripping the affected area are deposited in a polypropylene container with an airtight lid. These samples may be refrigerated for a maximum of 2 days, while freezing allows for extended conservation. Another benefit of PCR is that it allows detection of single nucleotide polymorphisms and thus analysis of possible resistance to azoles and other antifungals. Finally, microscopic visualization of Malassezia via tape or direct impression smear [118] may also support diagnosis of fungal HND, yet the utility of this method is questionable without species differentiation since Malassezia are common skin commensals. Should non-Malassezia fungi prove to be relevant contributors to HND, similar methods may be leveraged for identifying hypersensitivity and/or presence of non-Malassezia fungi.
Management
While topical first-line therapies for AD (i.e., corticosteroids, PDE4 inhibitors, calcineurin inhibitors) may be intolerable or ineffective in HND, promising options include antifungal agents and more recently, JAK inhibitors, OX40/OX40L inhibitors, and anti-IL-13 therapy. Currently, European guidelines for AD recommend topical (ketoconazole or ciclopirox olamine) or systemic (itraconazole or fluconazole) antifungal therapy for AD patients with HND, especially those with clear IgE sensitization to Malassezia spp. [119]. Some clinicians may add tacrolimus, as there is evidence of synergism with antifungals against Malassezia [120]. Pyrithione zinc, butenafine, and lactic acid topicals can be considered since they may decrease Malassezia burden [60, 121, 122], although their efficacy for HND is not well-established.
Oral antifungal agents have shown promising efficacy in the treatment of AD patients with Malassezia allergy. These agents have been associated with improved SCORing Atopic Dermatitis (SCORAD) scores, decreased topical steroid use, decreased Malassezia sIgE, and decreased total serum IgE [117, 123, 124]. A double-blind, placebo-controlled trial (DBPCT) showed that 200 mg oral ketoconazole for 30 days improves HND dermatitis with M. furfur sensitization [124]. Another DBPCT showed that 200 or 400 mg itraconazole monotherapy for 1 week improves HND severity for up to 6 weeks [123]. DAHND may also benefit from oral itraconazole therapy as observed over 4 weeks [125]. Currently, the persistence of HND relief with sustained oral antifungals remains unknown, and side effects must be considered as long-term systemic azole use may cause hepatotoxicity and hormone-related irregularities [126]. European guidelines recommend imidazole derivatives (i.e., fluconazole or itraconazole) over ketoconazole for systemic treatment given their superior benefit to side-effect ratios [119].
While topical antifungals may have lower penetration into Malassezia reservoirs (i.e., the hair follicle) and less compliance compared to systemic options [117], some evidence supports their use in HND. A DBPCT of HND patients showed significant improvement in investigator global assessment (IGA) score after 1 month of ciclopirox olamine cream applied twice daily (− 1.2 versus − 0.7 for placebo; P = 0.049) and a similar trend in EASI score (− 128.2 versus − 98.8 for placebo; P > 0.05) [127]. Efficacy was supported by rebound HND symptoms upon discontinuation of ciclopirox olamine resulting in worsened IGA (0.4 versus − 0.2 for placebo; P = 0.025) and EASI (37.7 versus 0.6 for placebo; P > 0.05) scores at 2 weeks [127]. Notably, M. furfur isolates may be more drug tolerant to azoles and ciclopirox olamine than other Malassezia spp. [61]. Meanwhile, topical ketoconazole applied twice daily was observed to improve facial rashes refractory to dupilumab in AD patients [116]. Another DBPCT found no difference between topical miconazole-hydrocortisone cream and ketoconazole shampoo versus hydrocortisone alone for head and neck AD [128]. Since both groups showed improvement in this study, the effect of topical antifungals alone could not be ascertained. Notably, topical ketoconazole twice daily has also been observed to improve DAHND [18].
Pooled phase 3 clinical trials have shown that oral JAK inhibitors such as baricitinib significantly improve HND severity in moderate-to-severe AD [17]. Baricitinib inhibits JAK1/JAK2 signal transduction in AD to decrease downstream release of cytokines including IL-5, which is thought to improve AD by inhibiting eosinophil activation and migration to the skin [129, 130]. These medications may also improve DAHND, as upadacitinib monotherapy following oral itraconazole produces sustained improvement for DAHND [125]. Importantly, oral JAK inhibitors may cause significant side effects including opportunistic infections (i.e., tuberculosis), reactivation of latent infections (i.e., herpes zoster), and increased risk for non-melanoma skin cancer [131]. Consequently, they should be reserved for cases when other methods fail or are contraindicated. For HND in mild-to-moderate AD, phase 2 and 3 trials suggest that topical JAK inhibitors such as ruxolitinib significantly improve severity, itch, and quality of life [132]. Topical JAK inhibitors carry lower risk of infectious complications compared to systemic therapy and application site reactions are rare, even in HND regions [132, 133].
Curiously, acneiform eruption has been associated with JAK inhibitor therapy [134, 135], representing another potentially fungal-mediated rash secondary to AD treatment. This “JAKne” occurs in up to 14% of patients on systemic JAK inhibitors in a dose-dependent manner with upadacitinib and abrocitinib showing a higher incidence than baricitinib [135, 136]. JAKne appears in the first months after starting treatment and presents as follicular and non-follicular erythematous papules most commonly on the face (Fig. 3) but also on the trunk (Fig. 4) [137]. Wood’s light shows a predominant yellow-orange fluorescence (compatible with Malassezia spp.), combined with red fluorescence of variable degree (compatible with Cutibacterium acnes). This examination is an important clinical finding of dysbiosis associated with JAK inhibitors, which can be confirmed by microbiological study. The dramatic improvement with oral antifungals (i.e., itraconazole or fluconazole) is another clinical finding that supports the suspicion of dysbiosis due to Malassezia spp. as a microorganism responsible for the acneiform eruption caused by these drugs (Figs. 3 and 4).
Fig. 3.
A Facial acneiform eruption 6 weeks after starting abrocitinib 200 mg daily. B Almost complete clearance of the acneiform eruption after application of ketoconazole 2% cream twice daily for 21 days. Abrocitinib was not discontinued
Fig. 4.
Truncal acneiform eruption 8 weeks after starting upadacitinib 30 mg daily. Yellow-orange combined with red fluorescence on Wood’s light examination compatible with Malassezia spp. and Cutibacterium acnes
OX40/40L inhibitors and anti-IL-13 therapy may be other options for HND on the horizon. Since the pathogenesis of HND involves T cell subsets expressing OX40, therapies targeting OX40/40L (i.e., rocatinlimab and amlitelimab) are logical options that act via modulation of effector T cell survival and expansion [138]. Indeed, HND patients with moderate-severe disease treated with rocatinlimab have shown improvement in severity compared to placebo in phase 2 trials [139] and rocatinlimab has been generally well-tolerated [138]. Finally, the anti-IL-13 monoclonal antibody tralokinumab appears safe and effective for HND for 16 weeks and may even treat cases of DAHND as mentioned above. More extensive clinical trials are needed to evaluate OX40/40L inhibitors and tralokinumab for HND.
Conclusion
HND presents unique challenges and may deviate from other forms of AD regarding etiology and optimal management strategies. The involvement of Malassezia spp. in HND is highly likely given enhanced sensitization to Malassezia among HND patients, demonstrated AD exacerbation upon Malassezia exposure in animal studies, and clinical improvement of HND with antifungals in human trials. Current understanding and management of fungal HND and DAHND is incomplete. For example, there remains controversy regarding HND pathophysiology (i.e., Th17 versus Th2 theories), and the contribution of non-Malassezia fungi is largely unknown. Alternative mechanisms for DAHND are also poorly studied. From a management perspective, the number of studies for treatment of HND and especially DAHND remains quite limited. Further clinical trials are necessary to confirm the safety and efficacy of existing therapies (i.e., antifungals, small molecules, and biologics) for HND, to determine optimal dosage and timing, and to evaluate combination therapies (i.e., antifungals plus immunosuppression). JAK inhibitors, OX40/40L inhibitors, and anti-IL-13 therapy are promising advanced therapies for HND. Finally, precision-medicine approaches for HND should consider demographic and environmental factors as they may influence the mycobiome composition and in turn affect disease severity. Thus, while the mechanisms and therapies for fungal HND require continued study and refinement, the identification of fungi as a major contributor to HND will perhaps enable a renaissance of better understanding and rational management for this disease.
Author Contribution
ACC conceptualized the project. ACC, FJNT, and MS performed the data collection. ACC wrote the manuscript with section contributions from FJNT and MS. ACC prepared Fig. 1. FJNT obtained patient consents and prepared Figs. 2–4. ACC, FJNT, MS, and COP reviewed and edited the manuscript. All authors approved the final submission.
Funding
Open access funding provided by SCELC, Statewide California Electronic Library Consortium
Availability of Data and Materials
Not applicable.
Declarations
Ethical Approval
Patient consents were obtained for all images included in the manuscript.
Conflict of Interest
The authors declare no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Reed B, Blaiss MS (2018) The burden of atopic dermatitis. Allergy Asthma Proc 39:406–410. 10.2500/aap.2018.39.4175 [DOI] [PubMed] [Google Scholar]
- 2.Chong AC, Schwartz A, Lang J et al (2024) Patients’ and caregivers’ preferences for mental health care and support in atopic dermatitis. Dermatitis 35:S70–S76. 10.1089/derm.2023.0111 [DOI] [PubMed] [Google Scholar]
- 3.Rønnstad ATM, Halling-Overgaard A-S, Hamann CR et al (2018) Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol 79:448-456.e30. 10.1016/j.jaad.2018.03.017 [DOI] [PubMed] [Google Scholar]
- 4.Patel KR, Immaneni S, Singam V et al (2019) Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol 80:402–410. 10.1016/j.jaad.2018.08.063 [DOI] [PubMed] [Google Scholar]
- 5.Long Q, Jin H, You X et al (2022) Eczema is a shared risk factor for anxiety and depression: a meta-analysis and systematic review. PLoS ONE 17:e0263334. 10.1371/journal.pone.0263334 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Smith Begolka W, Chovatiya R, Thibau IJ, Silverberg JI (2021) Financial burden of atopic dermatitis out-of-pocket health care expenses in the United States. Dermatitis 32:S62–S70. 10.1097/DER.0000000000000715 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Maarouf M, Saberian C, Lio PA, Shi VY (2018) Head-and-neck dermatitis: diagnostic difficulties and management pearls. Pediatr Dermatol 35:748–753. 10.1111/pde.13642 [DOI] [PubMed] [Google Scholar]
- 8.Girolomoni G, de Bruin-Weller M, Aoki V et al (2021) Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis 12:20406223211002980. 10.1177/20406223211002979 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Cabanillas B, Brehler A-C, Novak N (2017) Atopic dermatitis phenotypes and the need for personalized medicine. Curr Opin Allergy Clin Immunol 17:309–315. 10.1097/ACI.0000000000000376 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Silverberg JI, Hanifin JM (2013) Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 132:1132–1138. 10.1016/j.jaci.2013.08.031 [DOI] [PubMed] [Google Scholar]
- 11.Dhar S, Kanwar AJ (1998) Epidemiology and clinical pattern of atopic dermatitis in a North Indian pediatric population. Pediatr Dermatol 15:347–351. 10.1046/j.1525-1470.1998.1998015347.x [DOI] [PubMed] [Google Scholar]
- 12.Silverberg JI, Simpson B, Abuabara K et al (2023) Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol 89:519–528. 10.1016/j.jaad.2023.04.052 [DOI] [PubMed] [Google Scholar]
- 13.Lio PA, Wollenberg A, Thyssen JP et al (2020) Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol 19:943–948. 10.36849/JDD.2020.5422 [DOI] [PubMed] [Google Scholar]
- 14.Guglielmo A, Sechi A, Patrizi A et al (2021) Head and neck dermatitis, a subtype of atopic dermatitis induced by Malassezia spp: clinical aspects and treatment outcomes in adolescent and adult patients. Pediatr Dermatol 38:109–114. 10.1111/pde.14437 [DOI] [PubMed] [Google Scholar]
- 15.Atherton DJ (2003) Topical corticosteroids in atopic dermatitis. BMJ 327:942–943 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Hajar T, Leshem YA, Hanifin JM et al (2015) A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol 72:541-549.e2. 10.1016/j.jaad.2014.11.024 [DOI] [PubMed] [Google Scholar]
- 17.Wollenberg A, Lio P, Kleyn E et al (2022) Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five phase III clinical trials. Eur J Dermatol 32:522–529. 10.1684/ejd.2022.4280 [DOI] [PubMed] [Google Scholar]
- 18.Navarro-Triviño FJ, Ayén-Rodríguez Á (2022) Study of hypersensitivity to Malassezia furfur in patients with atopic dermatitis with head and neck pattern: is it useful as a biomarker and therapeutic indicator in these patients? Life (Basel) 12:299. 10.3390/life12020299 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Ashcroft DM, Dimmock P, Garside R et al (2005) Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 330:516. 10.1136/bmj.38376.439653.D3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Wollenberg A, Christen-Zäch S, Taieb A et al (2020) ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 34:2717–2744. 10.1111/jdv.16892 [DOI] [PubMed] [Google Scholar]
- 21.Fishbein AB, Silverberg JI, Wilson EJ, Ong PY (2020) Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract 8:91–101. 10.1016/j.jaip.2019.06.044 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Paller AS, Siegfried EC, Thaçi D et al (2020) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 83:1282–1293. 10.1016/j.jaad.2020.06.054 [DOI] [PubMed] [Google Scholar]
- 23.Soria A, Du-Thanh A, Seneschal J et al (2019) Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol 155:1312–1315. 10.1001/jamadermatol.2019.2613 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kozera E, Stewart T, Gill K et al (2022) Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study. Br J Dermatol 186:1050–1052. 10.1111/bjd.21019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Jo CE, Finstad A, Georgakopoulos JR et al (2021) Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol 84:1339–1347. 10.1016/j.jaad.2021.01.012 [DOI] [PubMed] [Google Scholar]
- 26.Muzumdar S, Zubkov M, Waldman R et al (2020) Characterizing dupilumab facial redness in children and adolescents: a single-institution retrospective chart review. J Am Acad Dermatol 83:1520–1521. 10.1016/j.jaad.2020.06.1003 [DOI] [PubMed] [Google Scholar]
- 27.Dybała A, Sernicola A, Gomes V et al (2022) Dupilumab facial redness: histologic characterization on a series of four cases. Immunotherapy 14:183–188. 10.2217/imt-2021-0122 [DOI] [PubMed] [Google Scholar]
- 28.Russo F, Cioppa V, Cartocci A et al (2024) Dupilumab and atopic dermatitis flares: an observational study to identify common clinical features in patients who have exacerbations despite biological therapy. Dermatitis 35:107–109. 10.1089/derm.2023.0011 [DOI] [PubMed] [Google Scholar]
- 29.Zhang E, Tanaka T, Tajima M et al (2011) Characterization of the skin fungal microbiota in patients with atopic dermatitis and in healthy subjects. Microbiol Immunol 55:625–632. 10.1111/j.1348-0421.2011.00364.x [DOI] [PubMed] [Google Scholar]
- 30.Schmid B, Künstner A, Fähnrich A et al (2022) Dysbiosis of skin microbiota with increased fungal diversity is associated with severity of disease in atopic dermatitis. J Eur Acad Dermatol Venereol 36:1811–1819. 10.1111/jdv.18347 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Chong AC, Visitsunthorn K, Ong PY (2022) Genetic/environmental contributions and immune dysregulation in children with atopic dermatitis. J Asthma Allergy 15:1681–1700. 10.2147/JAA.S293900 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Hwang J, Thompson A, Jaros J et al (2021) Updated understanding of Staphylococcus aureus in atopic dermatitis: from virulence factors to commensals and clonal complexes. Exp Dermatol 30:1532–1545. 10.1111/exd.14435 [DOI] [PubMed] [Google Scholar]
- 33.Szczepańska M, Blicharz L, Nowaczyk J et al (2022) The role of the cutaneous mycobiome in atopic dermatitis. J Fungus 8:1153. 10.3390/jof8111153 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P (2015) The role of Malassezia spp. in atopic dermatitis. J Clin Med 4:1217–1228. 10.3390/jcm4061217 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Sparber F, De Gregorio C, Steckholzer S et al (2019) The skin commensal yeast Malassezia triggers a type 17 response that coordinates anti-fungal immunity and exacerbates skin inflammation. Cell Host Microbe 25:389-403.e6. 10.1016/j.chom.2019.02.002 [DOI] [PubMed] [Google Scholar]
- 36.Findley K, Oh J, Yang J et al (2013) Topographic diversity of fungal and bacterial communities in human skin. Nature 498:367–370. 10.1038/nature12171 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Kaneko T, Makimura K, Abe M et al (2007) Revised culture-based system for identification of Malassezia species. J Clin Microbiol 45:3737–3742. 10.1128/JCM.01243-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Leeming JP, Notman FH, Holland KT (1989) The distribution and ecology of Malassezia furfur and cutaneous bacteria on human skin. J Appl Bacteriol 67:47–52. 10.1111/j.1365-2672.1989.tb04953.x [DOI] [PubMed] [Google Scholar]
- 39.Roberts SO (1969) Pityrosporum orbiculare: incidence and distribution on clinically normal skin. Br J Dermatol 81:264–269. 10.1111/j.1365-2133.1969.tb13978.x [DOI] [PubMed] [Google Scholar]
- 40.Roth RR, James WD (1988) Microbial ecology of the skin. Annu Rev Microbiol 42:441–464. 10.1146/annurev.mi.42.100188.002301 [DOI] [PubMed] [Google Scholar]
- 41.Nagata R, Nagano H, Ogishima D et al (2012) Transmission of the major skin microbiota, Malassezia, from mother to neonate. Pediatr Int 54:350–355. 10.1111/j.1442-200X.2012.03563.x [DOI] [PubMed] [Google Scholar]
- 42.Hobi S, Cafarchia C, Romano V, Barrs VR (2022) Malassezia: zoonotic implications, parallels and differences in colonization and disease in humans and animals. J Fungi (Basel) 8:708. 10.3390/jof8070708 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Gupta AK, Bluhm R, Cooper EA et al (2003) Seborrheic dermatitis. Dermatol Clin 21:401–412. 10.1016/s0733-8635(03)00028-7 [DOI] [PubMed] [Google Scholar]
- 44.Gao Z, Perez-Perez GI, Chen Y, Blaser MJ (2010) Quantitation of major human cutaneous bacterial and fungal populations. J Clin Microbiol 48:3575–3581. 10.1128/JCM.00597-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Gupta AK, Kohli Y (2004) Prevalence of Malassezia species on various body sites in clinically healthy subjects representing different age groups. Med Mycol 42:35–42. 10.1080/13693780310001610056 [DOI] [PubMed] [Google Scholar]
- 46.Leung MHY, Chan KCK, Lee PKH (2016) Skin fungal community and its correlation with bacterial community of urban Chinese individuals. Microbiome 4:46. 10.1186/s40168-016-0192-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Rahrovan S, Fanian F, Mehryan P et al (2018) Male versus female skin: what dermatologists and cosmeticians should know. Int J Womens Dermatol 4:122–130. 10.1016/j.ijwd.2018.03.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Man MQ, Xin SJ, Song SP et al (2009) Variation of skin surface pH, sebum content and stratum corneum hydration with age and gender in a large Chinese population. Skin Pharmacol Physiol 22:190–199. 10.1159/000231524 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Sugita T, Yamazaki T, Yamada S et al (2015) Temporal changes in the skin Malassezia microbiota of members of the Japanese Antarctic Research Expedition (JARE): a case study in Antarctica as a pseudo-space environment. Med Mycol 53:717–724. 10.1093/mmy/myv041 [DOI] [PubMed] [Google Scholar]
- 50.Sugita T, Yamazaki T, Makimura K et al (2016) Comprehensive analysis of the skin fungal microbiota of astronauts during a half-year stay at the International Space Station. Med Mycol 54:232–239. 10.1093/mmy/myv121 [DOI] [PubMed] [Google Scholar]
- 51.Leong C, Schmid B, Toi MJ et al (2019) Geographical and ethnic differences influence culturable commensal yeast diversity on healthy skin. Front Microbiol 10:1891. 10.3389/fmicb.2019.01891 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Park SK, Kim JS, Seo H-M (2022) Exposure to air pollution and incidence of atopic dermatitis in the general population: a national population-based retrospective cohort study. J Am Acad Dermatol 87:1321–1327. 10.1016/j.jaad.2021.05.061 [DOI] [PubMed] [Google Scholar]
- 53.Woo YR, Park S-Y, Choi K et al (2020) Air pollution and atopic dermatitis (AD): the impact of particulate matter (PM10) on an AD mouse-model. Int J Mol Sci 21:6079. 10.3390/ijms21176079 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Fadadu RP, Grimes B, Jewell NP et al (2021) Association of wildfire air pollution and health care use for atopic dermatitis and itch. JAMA Dermatol 157:1–9. 10.1001/jamadermatol.2021.0179 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Chong AC, Chwa WJ, Ong PY (2022) Aeroallergens in atopic dermatitis and chronic urticaria. Curr Allergy Asthma Rep 22:67–75. 10.1007/s11882-022-01033-2 [DOI] [PubMed] [Google Scholar]
- 56.Chueachavalit C, Meephansan J, Payungporn S et al (2022) Comparison of Malassezia spp. colonization between human skin exposed to high- and low-ambient air pollution. Exp Dermatol 31:1454–1461. 10.1111/exd.14622 [DOI] [PubMed] [Google Scholar]
- 57.Yan D, Li M, Si W et al (2023) Haze exposure changes the skin fungal community and promotes the growth of talaromyces strains. Microbiol Spectr 11:e0118822. 10.1128/spectrum.01188-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Kaga M, Sugita T, Nishikawa A et al (2011) Molecular analysis of the cutaneous Malassezia microbiota from the skin of patients with atopic dermatitis of different severities. Mycoses 54:e24-28. 10.1111/j.1439-0507.2009.01821.x [DOI] [PubMed] [Google Scholar]
- 59.Gaitanis G, Velegraki A, Alexopoulos EC et al (2009) Malassezia furfur fingerprints as possible markers for human phylogeography. ISME J 3:498–502. 10.1038/ismej.2008.112 [DOI] [PubMed] [Google Scholar]
- 60.Leong C, Wang J, Toi MJ et al (2021) Effect of zinc pyrithione shampoo treatment on skin commensal Malassezia. Med Mycol 59:210–213. 10.1093/mmy/myaa068 [DOI] [PubMed] [Google Scholar]
- 61.Jagielski T, Rup E, Ziółkowska A et al (2014) Distribution of Malassezia species on the skin of patients with atopic dermatitis, psoriasis, and healthy volunteers assessed by conventional and molecular identification methods. BMC Dermatol 14:3. 10.1186/1471-5945-14-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Sandström Falk MH, Tengvall Linder M, Johansson C et al (2005) The prevalence of Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta Derm Venereol 85:17–23. 10.1080/00015550410022276 [DOI] [PubMed] [Google Scholar]
- 63.Sugita T, Suto H, Unno T et al (2001) Molecular analysis of Malassezia microflora on the skin of atopic dermatitis patients and healthy subjects. J Clin Microbiol 39:3486–3490. 10.1128/JCM.39.10.3486-3490.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Nakabayashi A, Sei Y, Guillot J (2000) Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol 38:337–341. 10.1080/mmy.38.5.337.341 [DOI] [PubMed] [Google Scholar]
- 65.Chng KR, Tay ASL, Li C et al (2016) Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. Nat Microbiol 1:16106. 10.1038/nmicrobiol.2016.106 [DOI] [PubMed] [Google Scholar]
- 66.Danby SG, Cork MJ (2018) pH in atopic dermatitis. Curr Probl Dermatol 54:95–107. 10.1159/000489523 [DOI] [PubMed] [Google Scholar]
- 67.Knor T, Meholjić-Fetahović A, Mehmedagić A (2011) Stratum corneum hydration and skin surface pH in patients with atopic dermatitis. Acta Dermatovenerol Croat 19:242–247 [PubMed] [Google Scholar]
- 68.Selander C, Zargari A, Möllby R et al (2006) Higher pH level, corresponding to that on the skin of patients with atopic eczema, stimulates the release of Malassezia sympodialis allergens. Allergy 61:1002–1008. 10.1111/j.1398-9995.2006.01108.x [DOI] [PubMed] [Google Scholar]
- 69.López-García B, Lee PHA, Yamasaki K, Gallo RL (2005) Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 125:108–115. 10.1111/j.0022-202X.2005.23713.x [DOI] [PubMed] [Google Scholar]
- 70.Järvå M, Phan TK, Lay FT et al (2018) Human β-defensin 2 kills Candida albicans through phosphatidylinositol 4,5-bisphosphate–mediated membrane permeabilization. Sci Adv 4:eaat0979. 10.1126/sciadv.aat0979 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Ong PY, Ohtake T, Brandt C et al (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347:1151–1160. 10.1056/NEJMoa021481 [DOI] [PubMed] [Google Scholar]
- 72.Agerberth B, Buentke E, Bergman P et al (2006) Malassezia sympodialis differently affects the expression of LL-37 in dendritic cells from atopic eczema patients and healthy individuals. Allergy 61:422–430. 10.1111/j.1398-9995.2005.00952.x [DOI] [PubMed] [Google Scholar]
- 73.Jain C, Das S, Ramachandran VG et al (2017) Malassezia yeast and cytokine gene polymorphism in atopic dermatitis. J Clin Diagn Res 11:DC01–DC05. 10.7860/JCDR/2017/23948.9474 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Kim K, Hong J, Park J et al (2007) Association of interleukin-10 gene promoter polymorphism in Korean children with atopic dermatitis. J Allergy Clin Immunol 119:S280. 10.1016/j.jaci.2006.12.467 [Google Scholar]
- 75.Hussein YM, Ahmad AS, Ibrahem MM et al (2009) Interferon gamma gene polymorphism as a biochemical marker in Egyptian atopic patients. J Investig Allergol Clin Immunol 19:292–298 [PubMed] [Google Scholar]
- 76.Johansson C, Sandström MH, Bartosik J et al (2003) Atopy patch test reactions to Malassezia allergens differentiate subgroups of atopic dermatitis patients. Br J Dermatol 148:479–488. 10.1046/j.1365-2133.2003.05093.x [DOI] [PubMed] [Google Scholar]
- 77.Leung DY (1993) Role of IgE in atopic dermatitis. Curr Opin Immunol 5:956–962. 10.1016/0952-7915(93)90112-6 [DOI] [PubMed] [Google Scholar]
- 78.Kroner JW, Kyzy AB, Burkle JW et al (2020) Atopic dermatitis independently increases sensitization above parental atopy: the MPAACH study. J Allergy Clin Immunol 145:1464–1466. 10.1016/j.jaci.2020.01.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Brodská P, Panzner P, Pizinger K, Schmid-Grendelmeier P (2014) IgE-mediated sensitization to malassezia in atopic dermatitis: more common in male patients and in head and neck type. Dermatitis 25:120–126. 10.1097/DER.0000000000000040 [DOI] [PubMed] [Google Scholar]
- 80.Devos SA, van der Valk PG (2000) The relevance of skin prick tests for Pityrosporum ovale in patients with head and neck dermatitis. Allergy 55:1056–1058. 10.1034/j.1398-9995.2000.00782.x [DOI] [PubMed] [Google Scholar]
- 81.Chu H, Kim SM, Zhang K et al (2023) Head and neck dermatitis is exacerbated by Malassezia furfur colonization, skin barrier disruption, and immune dysregulation. Front Immunol 14:1114321. 10.3389/fimmu.2023.1114321 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Gupta AK, Kohli Y, Summerbell RC, Faergemann J (2001) Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 39:243–251. 10.1080/mmy.39.3.243.251 [DOI] [PubMed] [Google Scholar]
- 83.Hamid Q, Boguniewicz M, Leung DY (1994) Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94:870–876. 10.1172/JCI117408 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Saunte DML, Gaitanis G, Hay RJ (2020) Malassezia-associated skin diseases, the use of diagnostics and treatment. Front Cell Infect Microbiol 10:112. 10.3389/fcimb.2020.00112 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Fujii M (2021) The pathogenic and therapeutic implications of ceramide abnormalities in atopic dermatitis. Cells 10:2386. 10.3390/cells10092386 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Bayrou O, Pecquet C, Flahault A et al (2005) Head and neck atopic dermatitis and Malassezia-furfur-specific IgE antibodies. Dermatology 211:107–113. 10.1159/000086438 [DOI] [PubMed] [Google Scholar]
- 87.Lindsø Andersen P, Jemec GB, Erikstrup C et al (2023) Human leukocyte antigen system associations in Malassezia-related skin diseases. Arch Dermatol Res 315:895–902. 10.1007/s00403-022-02454-9 [DOI] [PubMed] [Google Scholar]
- 88.Zargari A, Selander C, Rasool O et al (2007) Mala s 12 is a major allergen in patients with atopic eczema and has sequence similarities to the GMC oxidoreductase family. Allergy 62:695–703. 10.1111/j.1398-9995.2006.01291.x [DOI] [PubMed] [Google Scholar]
- 89.Vilhelmsson M, Ekman GJ, Zargari A, Scheynius A (2004) The Malassezia sympodialis allergen mala s 11 with sequence similarity to manganese superoxide dismutase induces maturation and production of inflammatory cytokines in human dendritic cells. Scand J Immunol 59:622. 10.1111/j.0300-9475.2004.01423ae.x [Google Scholar]
- 90.Balaji H, Heratizadeh A, Wichmann K et al (2011) Malassezia sympodialis thioredoxin-specific T cells are highly cross-reactive to human thioredoxin in atopic dermatitis. J Allergy Clin Immunol 128:92-99.e4. 10.1016/j.jaci.2011.02.043 [DOI] [PubMed] [Google Scholar]
- 91.Ribbing C, Engblom C, Lappalainen J et al (2011) Mast cells generated from patients with atopic eczema have enhanced levels of granule mediators and an impaired Dectin-1 expression. Allergy 66:110–119. 10.1111/j.1398-9995.2010.02437.x [DOI] [PubMed] [Google Scholar]
- 92.Desai A, Jung M-Y, Olivera A et al (2016) IL-6 promotes an increase in human mast cell number and reactivity through suppression of SOCS3. J Allergy Clin Immunol 137:1863-1871.e6. 10.1016/j.jaci.2015.09.059 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Hiragun T, Ishii K, Hiragun M et al (2013) Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients. J Allergy Clin Immunol 132:608-615.e4. 10.1016/j.jaci.2013.03.047 [DOI] [PubMed] [Google Scholar]
- 94.Kohsaka T, Hiragun T, Ishii K et al (2018) Different hypersensitivities against homologous proteins of MGL_1304 in patients with atopic dermatitis. Allergol Int 67:103–108. 10.1016/j.alit.2017.05.009 [DOI] [PubMed] [Google Scholar]
- 95.Koyama T, Kanbe T, Ishiguro A et al (2000) Isolation and characterization of a major antigenic component of Malassezia globosa to IgE antibodies in sera of patients with atopic dermatitis. Microbiol Immunol 44:373–379. 10.1111/j.1348-0421.2000.tb02508.x [DOI] [PubMed] [Google Scholar]
- 96.Goh JPZ, Ruchti F, Poh SE et al (2022) The human pathobiont Malassezia furfur secreted protease Mfsap1 regulates cell dispersal and exacerbates skin inflammation. Proc Natl Acad Sci U S A 119:e2212533119. 10.1073/pnas.2212533119 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Edslev SM, Andersen PS, Agner T et al (2021) Identification of cutaneous fungi and mites in adult atopic dermatitis: analysis by targeted 18S rRNA amplicon sequencing. BMC Microbiol 21:72. 10.1186/s12866-021-02139-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Bjerre RD, Bandier J, Skov L et al (2017) The role of the skin microbiome in atopic dermatitis: a systematic review. Br J Dermatol 177:1272–1278. 10.1111/bjd.15390 [DOI] [PubMed] [Google Scholar]
- 99.Katoh N, Ohya Y, Ikeda M et al (2020) Japanese guidelines for atopic dermatitis 2020. Allergol Int 69:356–369. 10.1016/j.alit.2020.02.006 [DOI] [PubMed] [Google Scholar]
- 100.Choi Y, Park KY, Han HS et al (2022) Comparative Analysis of cutaneous fungi in atopic dermatitis patients and healthy individuals. Ann Dermatol 34:118. 10.5021/ad.2022.34.2.118 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Sugita T, Suzuki M, Goto S et al (2010) Quantitative analysis of the cutaneous Malassezia microbiota in 770 healthy Japanese by age and gender using a real-time PCR assay. Med Mycol 48:229–233. 10.1080/13693780902977976 [DOI] [PubMed] [Google Scholar]
- 102.Sugita T, Saito M, Ito T et al (2003) The basidiomycetous yeasts Cryptococcus diffluens and C. liquefaciens colonize the skin of patients with atopic dermatitis. Microbiol Immunol 47:945–950. 10.1111/j.1348-0421.2003.tb03468.x [DOI] [PubMed] [Google Scholar]
- 103.Kato H, Sugita T, Ishibashi Y, Nishikawa A (2007) Evaluation of the levels of specific IgE against Cryptococcus diffluens and Cryptococcus liquefaciens in patients with atopic dermatitis. Microbiol Immunol 51:945–950. 10.1111/j.1348-0421.2007.tb03991.x [DOI] [PubMed] [Google Scholar]
- 104.Savolainen J, Kosonen J, Lintu P et al (1999) Candida albicans mannan- and protein-induced humoral, cellular and cytokine responses in atopic dermatitis patients. Clin Exp Allergy 29:824–831. 10.1046/j.1365-2222.1999.00555.x [DOI] [PubMed] [Google Scholar]
- 105.Thammahong A, Kiatsurayanon C, Edwards SW et al (2020) The clinical significance of fungi in atopic dermatitis. Int J Dermatol 59:926–935. 10.1111/ijd.14941 [DOI] [PubMed] [Google Scholar]
- 106.Harb H, Chatila TA (2020) Mechanisms of dupilumab. Clin Exp Allergy 50:5–14. 10.1111/cea.13491 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Bax CE, Khurana MC, Treat JR et al (2021) New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis. Pediatr Dermatol 38:390–394. 10.1111/pde.14499 [DOI] [PubMed] [Google Scholar]
- 108.de Wijs LEM, Nguyen NT, Kunkeler ACM et al (2020) Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol 183:745–749. 10.1111/bjd.18730 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Bangert C, Alkon N, Chennareddy S et al (2024) Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun 15:2839. 10.1038/s41467-024-46540-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Buentke E, Heffler LC, Wallin RP et al (2001) The allergenic yeast Malassezia furfur induces maturation of human dendritic cells. Clin Exp Allergy 31:1583–1593. 10.1046/j.1365-2222.2001.01199.x [DOI] [PubMed] [Google Scholar]
- 111.Kirchner FR, LeibundGut-Landmann S (2021) Tissue-resident memory Th17 cells maintain stable fungal commensalism in the oral mucosa. Mucosal Immunol 14:455–467. 10.1038/s41385-020-0327-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Umemoto N, Kakurai M, Matsumoto T et al (2024) Dupilumab alters both the bacterial and fungal skin microbiomes of patients with atopic dermatitis. Microorganisms 12:224. 10.3390/microorganisms12010224 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Wang W, Liu E, Li X et al (2022) CCL21 contributes to Th17 cell migration in neuroinflammation in obese mice following lead exposure. Toxicol Lett 366:7–16. 10.1016/j.toxlet.2022.06.003 [DOI] [PubMed] [Google Scholar]
- 114.Schlösser AR, Shareef M, Olydam J et al (2023) Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clin Exp Dermatol 48:510–517. 10.1093/ced/llad038 [DOI] [PubMed] [Google Scholar]
- 115.Navarro-Triviño FJ, Salazar-Nievas M, Sanz-Cabanillas JL, Arjona-Aguilera C (2024) Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: a multicentre study of 12 patients. Australas J Dermatol 65:260–265. 10.1111/ajd.14264 [DOI] [PubMed] [Google Scholar]
- 116.Okiyama N, Nakamura Y, Ishitsuka Y et al (2020) Successful topical treatment with ketoconazole for facial rashes refractory to dupilumab in patients with atopic dermatitis: case reports. J Eur Acad Dermatol Venereol 34:e474–e476. 10.1111/jdv.16383 [DOI] [PubMed] [Google Scholar]
- 117.Darabi K, Hostetler SG, Bechtel MA, Zirwas M (2009) The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol 60:125–136. 10.1016/j.jaad.2008.07.058 [DOI] [PubMed] [Google Scholar]
- 118.Bloom P (2022) The latest in diagnosis and management of Malassezia dermatitis. DMV360 53:30. https://www.dvm360.com/view/the-latest-in-diagnosis-and-management-of-malassezia-dermatitis
- 119.Wollenberg A, Barbarot S, Bieber T et al (2018) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 32:850–878. 10.1111/jdv.14888 [DOI] [PubMed] [Google Scholar]
- 120.Sugita T, Tajima M, Ito T et al (2005) Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol 43:2824–2829. 10.1128/JCM.43.6.2824-2829.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Gupta A, Yokou M, Arika T, Bucks D (2000) Evaluation of the in vitro and in vivo efficacy of butenafine hydrochloride cream 1% against Malassezia furfur species and seborrheic dermatitis. J Dermatol Treat 11:79–83. 10.1080/09546630050517450 [Google Scholar]
- 122.Matousek JL, Campbell KL, Kakoma I et al (2003) Evaluation of the effect of pH on in vitro growth of Malassezia pachydermatis. Can J Vet Res 67:56–59 [PMC free article] [PubMed] [Google Scholar]
- 123.Svejgaard E, l, Larsen PØ, Deleuran M, et al (2004) Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. J Eur Acad Dermatol Venereol 18:445–449. 10.1111/j.1468-3083.2004.00963.x [DOI] [PubMed] [Google Scholar]
- 124.Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K (2001) Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 56:512–517. 10.1034/j.1398-9995.2001.056006512.x [DOI] [PubMed] [Google Scholar]
- 125.Kozera E, Flora A, Stewart T et al (2023) Dupilumab-associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with Malassezia-specific immunoglobulin E levels mirroring clinical response. J Am Acad Dermatol 88:255–257. 10.1016/j.jaad.2022.05.021 [DOI] [PubMed] [Google Scholar]
- 126.Benitez LL, Carver PL (2019) Adverse effects associated with long-term administration of azole antifungal agents. Drugs 79:833–853. 10.1007/s40265-019-01127-8 [DOI] [PubMed] [Google Scholar]
- 127.Mayser P, Kupfer J, Nemetz D et al (2006) Treatment of head and neck dermatitis with ciclopiroxolamine cream–results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 19:153–158. 10.1159/000092596 [DOI] [PubMed] [Google Scholar]
- 128.Broberg A, Faergemann J (1995) Topical antimycotic treatment of atopic dermatitis in the head/neck area. A double-blind randomised study. Acta Derm Venereol 75:46–49. 10.2340/00015555754649 [DOI] [PubMed] [Google Scholar]
- 129.Melo A, Carrascosa JM, Torres T (2022) Baricitinib for the treatment of atopic dermatitis. J Dermatolog Treat 33:2404–2413. 10.1080/09546634.2021.1967268 [DOI] [PubMed] [Google Scholar]
- 130.Hoy SM (2022) Baricitinib: a review in moderate to severe atopic dermatitis. Am J Clin Dermatol 23:409–420. 10.1007/s40257-022-00684-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Nash P, Kerschbaumer A, Dörner T et al (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 80:71–87. 10.1136/annrheumdis-2020-218398 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Simpson EL, Bissonnette R, Chiesa Fuxench ZC et al (2024) Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies. J Dermatolog Treat 35:2310633. 10.1080/09546634.2024.2310633 [DOI] [PubMed] [Google Scholar]
- 133.Samuel C, Cornman H, Kambala A, Kwatra SG (2023) A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb) 13:729–749. 10.1007/s13555-023-00892-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Ballanger F, Auffret N, Leccia M-T et al (2023) Acneiform lesions but not acne after treatment with Janus kinase inhibitors: diagnosis and management of Janus kinase-acne. Acta Derm Venereol 103:11657. 10.2340/actadv.v103.11657 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Guo L, Feng S, Sun B et al (2020) Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol 34:192–201. 10.1111/jdv.15937 [DOI] [PubMed] [Google Scholar]
- 136.Sun C, Su Z, Zeng Y-P (2023) Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis. Inflamm Res 72:1861–1871. 10.1007/s00011-023-01789-x [DOI] [PubMed] [Google Scholar]
- 137.Avallone G, Mastorino L, Tavoletti G et al (2024) Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: a multicenter retrospective study. J Am Acad Dermatol 90:1031–1034. 10.1016/j.jaad.2024.01.004 [DOI] [PubMed] [Google Scholar]
- 138.Guttman-Yassky E, Simpson EL, Reich K et al (2023) An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 401:204–214. 10.1016/S0140-6736(22)02037-2 [DOI] [PubMed] [Google Scholar]
- 139.Guttman-Yassky E, Esfandiari E, Chong C et al (2022) Rocatinlimab* (AMG 451/KHK4083) demonstrates improvements in head and neck atopic dermatitis in patients with moderate-severe disease in a phase 2 trial. In: Proceedings of the 31st European Academy of Dermatology and Venereology (EADV) Congress. Milan, Italy
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.




